Researchers confirm IASLC proposed characterization of uncertain R Status R(un), prognosis between R0 and R1

Researchers at VCU identify Achilles’ heel in lung cancer through common genetic mutation

A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA replication in cancer cells.

March 13, 2026

Vol.52 No.10

Clinical Roundup

Growing number of U.S. adults wrongly think vaping is more harmful than smoking cigarettes, study shows

A growing number of U.S. adults consider electronic cigarettes (e-cigarettes) more harmful than conventional cigarettes, UT Southwestern Medical Center researchers show in a study.

March 13, 2026

Vol.52 No.10

Clinical Roundup

Lung cancer drug offers a surprising new treatment against ovarian cancer, Mayo study finds

Ovarian cancer cells may quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better, a study published by Mayo Clinic researchers suggests.

February 20, 2026

Vol.52 No.07

Clinical Trials & Tribulations

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease. The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

January 16, 2026

Vol.52 No.02

By Kevin King

Clinical Trials & Tribulations

How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx

Lung cancer remains the leading cause of cancer death in the United States, largely because it is most often diagnosed at an advanced stage.

Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds

Personalis Inc. announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, which demonstrated the clinical importance of ultrasensitive, tumor-informed molecular residual disease testing in stage 1 to 3 non-small cell lung cancer.

December 19, 2025

Vol.51 No.46

Researchers confirm IASLC proposed characterization of uncertain R Status R(un), prognosis between R0 and R1

YOU MAY BE INTERESTED IN

Researchers at VCU identify Achilles’ heel in lung cancer through common genetic mutation

Growing number of U.S. adults wrongly think vaping is more harmful than smoking cigarettes, study shows

Lung cancer drug offers a surprising new treatment against ovarian cancer, Mayo study finds

A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers

How a Montefiore Einstein screening program is changing the history of lung cancer in the Bronx

Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds

Renew today!

Subscriber content

Never miss an issue!

Login